{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:16:00Z","timestamp":1769112960909,"version":"3.49.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T00:00:00Z","timestamp":1482192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10495-016-1338-y","type":"journal-article","created":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T15:25:46Z","timestamp":1482247546000},"page":"393-405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["5-Flurouracil disrupts nuclear export and nuclear pore permeability in a calcium dependent manner"],"prefix":"10.1007","volume":"22","author":[{"given":"Kelly J.","family":"Higby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa M.","family":"Bischak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca G.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Broskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarrett A.","family":"Koper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey C.","family":"Nickle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen K.","family":"Resendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,20]]},"reference":[{"key":"1338_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18632\/oncotarget.1457","volume":"5","author":"R Hill","year":"2013","unstructured":"Hill R, Cautain B, Pedro Nd, Link W (2013) Targeting nucleocytoplasmic transport in cancer therapy. Oncotarget 5:11\u201328","journal-title":"Oncotarget"},{"key":"1338_CR2","doi-asserted-by":"crossref","unstructured":"Cautain B, Hill R, Pedro N, Link W. (2015) Components and regulation of nuclear transport processes. FEBS J 282:445\u2013462","DOI":"10.1111\/febs.13163"},{"key":"1338_CR3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrc1274","volume":"4","author":"T Kau","year":"2004","unstructured":"Kau T, Way J, Silver P (2004) Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer 4:106\u2013117","journal-title":"Nat Rev Cancer"},{"key":"1338_CR4","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.cdd.4401626","volume":"12","author":"E Ferrando-May","year":"2005","unstructured":"Ferrando-May E (2005) Nucleocytoplasmic transport in apoptosis. Cell Death Differ 12:1263\u20131276","journal-title":"Cell Death Differ"},{"key":"1338_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1139\/y05-100","volume":"84","author":"B Fahrenkrog","year":"2006","unstructured":"Fahrenkrog B (2006) The nuclear pore complex, nuclear transport and apoptosis. Can J Physiol Pharmacol 84:279\u2013286","journal-title":"Can J Physiol Pharmacol"},{"key":"1338_CR6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","volume":"83","author":"JG Turner","year":"2012","unstructured":"Turner JG, Dawson J, Sullivan DM (2012) Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 83:1021\u20131032","journal-title":"Biochem Pharmacol"},{"key":"1338_CR7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","volume":"157","author":"JC Reed","year":"2000","unstructured":"Reed JC (2000) Mechanisms of apoptosis. Am J Pathol 157:1415\u20131430","journal-title":"Am J Pathol"},{"key":"1338_CR8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1074\/jbc.M511717200","volume":"281","author":"M Patre","year":"2006","unstructured":"Patre M, Tabbert A, Hermann D et al (2006) Caspases target only two architectural components within the core structure of the nuclear pore complex. J Biol Chem 281:1296\u20131304","journal-title":"J Biol Chem"},{"key":"1338_CR9","doi-asserted-by":"crossref","first-page":"114-121","DOI":"10.1016\/j.plantsci.2012.09.009","volume":"197","author":"F Dom\u00ednguez","year":"2012","unstructured":"Dom\u00ednguez F, Cejudo FJ (2012) A comparison between nuclear dismantling during plant and animal programmed cell death. Plant Sci 197:114-121","journal-title":"Plant Sci"},{"key":"1338_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.cdd.4400837","volume":"8","author":"E Ferrando-May","year":"2001","unstructured":"Ferrando-May E, Cordes V, Biller-Ckovric I, Mirkovic J, G\u00f6rlich D, Nicotera P (2001) Caspases mediate nucleoporin cleavage, but not early redistribution of nuclear transport factors and modulation of nuclear permeability in apoptosis. Cell Death Differ 8:495\u2013505","journal-title":"Cell Death Differ"},{"key":"1338_CR11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.cdd.4401432","volume":"11","author":"M Kodiha","year":"2004","unstructured":"Kodiha M, Chu A, Matusiewicz N, Stochaj U (2004) Multiple mechanisms promote the inhibition of classical nuclear import upon exposure to severe oxidative stress. Cell Death Differ 11:862\u2013874","journal-title":"Cell Death Differ"},{"key":"1338_CR12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.yexcr.2003.10.019","volume":"293","author":"M Kihlmark","year":"2004","unstructured":"Kihlmark M, Rustum C, Eriksson C, Beckman M, Iverfeldt K, Hallberg E (2004) Correlation between nucleocytoplasmic transport and caspase-3-dependent dismantling of nuclear pores during apoptosis. Exp Cell Res 293:346\u2013356","journal-title":"Exp Cell Res"},{"key":"1338_CR13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1083\/jcb.151.5.951","volume":"151","author":"L Faleiro","year":"2000","unstructured":"Faleiro L, Lazebnik Y (2000) Caspases disrupt the nuclear-cytoplasmic barrier. J Cell Biol 151:951\u2013960","journal-title":"J Cell Biol"},{"key":"1338_CR14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.nano.2010.04.006","volume":"6","author":"A Kramer","year":"2010","unstructured":"Kramer A, Liashkovich I, Oberleithner H, Shahin V (2010) Caspase-9-dependent decrease of nuclear pore channel hydrophobicity is accompanied by nuclear envelope leakiness. Nanomedicine 6:605\u2013611","journal-title":"Nanomedicine"},{"key":"1338_CR15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4161\/nucl.21982","volume":"3","author":"C Strasser","year":"2012","unstructured":"Strasser C, Grote P, Sch\u00e4uble K, Ganz M, Ferrando-May E (2012) Regulation of nuclear envelope permeability in cell death and survival. Nucleus 3:540\u2013551","journal-title":"Nucleus"},{"key":"1338_CR16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncb1810","volume":"11","author":"C Wong","year":"2009","unstructured":"Wong C, Chan H, Ho C et al (2009) Apoptotic histone modification inhibits nuclear transport by regulating RCC1. Nat Cell Biol 11:36\u201345","journal-title":"Nat Cell Biol"},{"key":"1338_CR17","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.bjc.6601336","volume":"89","author":"R Nagourney","year":"2003","unstructured":"Nagourney R, Sommers B, Harper S, Radecki S (2003) Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. Br J Cancer 89:1789\u20131795","journal-title":"Br J Cancer"},{"key":"1338_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"J Lee","year":"2016","unstructured":"Lee J, Beumer J, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78:447\u2013464","journal-title":"Cancer Chemother Pharmacol"},{"key":"1338_CR19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3892\/ol.2012.965","volume":"5","author":"EM Saleh","year":"2013","unstructured":"Saleh EM, El-Awady RA, Anis N (2013) Predictive markers for the response to 5-fluorouracil therapy in cancer cells: constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy. Oncol Lett 5:321\u2013327","journal-title":"Oncol Lett"},{"key":"1338_CR20","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1006\/bbrc.2001.4571","volume":"282","author":"M Azuma","year":"2001","unstructured":"Azuma M, Yamashita T, Aota K, Tamatani T, Sato M (2001) 5-Fluorouracil suppression of NF-\u03baB is mediated by the inhibition of I\u03baB kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282:292\u2013296","journal-title":"Biochem Biophys Res Commun"},{"key":"1338_CR21","doi-asserted-by":"crossref","first-page":"e89848","DOI":"10.1371\/journal.pone.0089848","volume":"9","author":"S Wang","year":"2014","unstructured":"Wang S, Han X, Wang J, Yao J, Shi Y (2014) Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts. PLoS One 9:e89848","journal-title":"PLoS One"},{"key":"1338_CR22","doi-asserted-by":"crossref","first-page":"15387","DOI":"10.1073\/pnas.242259599","volume":"99","author":"BL Staker","year":"2002","unstructured":"Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA 99:15387\u201315392","journal-title":"Proc Natl Acad Sci USA"},{"key":"1338_CR23","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","volume":"13","author":"Y Xu","year":"2002","unstructured":"Xu Y, Villalona-Calero MA (2002) Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 13:1841\u20131851","journal-title":"Ann Oncol"},{"key":"1338_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/cbt.199","volume":"2","author":"V Malhotra","year":"2003","unstructured":"Malhotra V, Perry MC (2003) Classical chemotherapy: mechanisms, toxicities and the therapeutic window. Cancer Biol Ther 2:1\u20133","journal-title":"Cancer Biol Ther"},{"key":"1338_CR25","doi-asserted-by":"crossref","unstructured":"Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440\u2013450","DOI":"10.1016\/j.molmed.2006.07.007"},{"key":"1338_CR26","first-page":"1664","volume":"56","author":"MK Danks","year":"1996","unstructured":"Danks MK, Garrett KE, Marion RC, Whipple DO (1996) Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res 56:1664\u20131673","journal-title":"Cancer Res"},{"key":"1338_CR27","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1073\/pnas.95.18.10608","volume":"95","author":"DC Love","year":"1998","unstructured":"Love DC, Sweitzer TD, Hanover JA (1998) Reconstitution of HIV-1 rev nuclear export: independent requirements for nuclear import and export. Proc Natl Acad Sci USA 95:10608\u201310613","journal-title":"Proc Natl Acad Sci USA"},{"key":"1338_CR28","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3892\/ol.2012.829","volume":"4","author":"LU Chuang-Xin","year":"2012","unstructured":"Chuang-Xin LU, Wen-Yu W, Yao CUI, Xiao-Yan LI, Yun Z (2012) Quercetin enhances the effects of 5-fluorouracil-mediated growth inhibition and apoptosis of esophageal cancer cells by inhibiting NF-\u03baB. Oncol Lett 4:775\u2013778","journal-title":"Oncol Lett"},{"key":"1338_CR29","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1074\/jbc.M108263200","volume":"277","author":"Y-Y Mo","year":"2002","unstructured":"Mo Y-Y, Yu Y, Shen Z, Beck WT (2002) Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J Biol Chem 277:2958\u20132964","journal-title":"J Biol Chem"},{"key":"1338_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.canlet.2005.03.022","volume":"233","author":"KT Papazisis","year":"2006","unstructured":"Papazisis KT, Kalemi TG, Zambouli D et al (2006) Synergistic effects of protein tyrosine kinase inhibitor genistein with camptothecins against three cell lines in vitro. Cancer Lett 233:255\u2013264","journal-title":"Cancer Lett"},{"key":"1338_CR31","doi-asserted-by":"crossref","unstructured":"Preston SF, Berlin RD (1992) An intracellular calcium store regulates protein synthesis in HeLa cells, but it is not the hormone-sensitive store. Cell Calcium 13:303\u2013312","DOI":"10.1016\/0143-4160(92)90065-Z"},{"key":"1338_CR32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1042\/bj3000665","volume":"300","author":"AJ Morgan","year":"1994","unstructured":"Morgan AJ, Jacob R (1994) Ionomycin enhances Ca2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane. Biochem J 300:665\u2013672","journal-title":"Biochem J"},{"key":"1338_CR33","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1021\/tx200109y","volume":"24","author":"G Amodio","year":"2011","unstructured":"Amodio G, Moltedo O, Monteleone F et al (2011) Proteomic signatures in thapsigargin-treated hepatoma cells. Chem Res Toxicol 24:1215\u20131222","journal-title":"Chem Res Toxicol"},{"key":"1338_CR34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.bjc.6601336","volume":"89","author":"RA Nagourney","year":"2003","unstructured":"Nagourney RA, Sommers BL, Harper SM, Radecki S, Evans SS (2003) Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics. Br J Cancer 89:1789\u20131795","journal-title":"Br J Cancer"},{"key":"1338_CR35","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0006-2952(98)00205-6","volume":"56","author":"V Pavillard","year":"1998","unstructured":"Pavillard V, Formento P, Rostagno P et al (1998) Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 56:1315\u20131322","journal-title":"Biochem Pharmacol"},{"key":"1338_CR36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"1338_CR37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1081\/CNV-120002489","volume":"20","author":"EI Sbar","year":"2002","unstructured":"Sbar EI, Khatri J, Rodman WD et al (2002) Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies. Cancer Invest 20:644\u2013650","journal-title":"Cancer Invest"},{"key":"1338_CR38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/modpathol.2009.14","volume":"22","author":"A Faggad","year":"2009","unstructured":"Faggad A, Darb-Esfahani S, Wirtz R et al (2009) Topoisomerase II alpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis. Mod Pathol 22:579\u2013588","journal-title":"Mod Pathol"},{"key":"1338_CR39","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3892\/ijo.2012.1506","volume":"41","author":"AK Yadunandam","year":"2012","unstructured":"Yadunandam AK, Yoon JS, Seong YA, Oh CW, Kim GD (2012) Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells. Int J Oncol 41:1036\u20131042","journal-title":"Int J Oncol"},{"key":"1338_CR40","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1038\/onc.2012.467","volume":"32","author":"G Can","year":"2013","unstructured":"Can G, Akpinar B, Baran Y, Zhivotovsky B, Olsson M (2013) 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells. Oncogene 32:4529\u20134538","journal-title":"Oncogene"},{"key":"1338_CR41","first-page":"124","volume":"19","author":"U Ziegler","year":"2004","unstructured":"Ziegler U, Groscurth P (2004) Morphological features of cell death. News Physiol Sci 19:124\u2013128","journal-title":"News Physiol Sci"},{"key":"1338_CR42","doi-asserted-by":"crossref","first-page":"e20276","DOI":"10.1371\/journal.pone.0020276","volume":"6","author":"L Stevenson","year":"2011","unstructured":"Stevenson L, Allen WL, Proutski I et al (2011) Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. PLoS One 6:e20276","journal-title":"PLoS One"},{"key":"1338_CR43","doi-asserted-by":"crossref","first-page":"12593","DOI":"10.1074\/jbc.R800076200","volume":"284","author":"JA Hanover","year":"2009","unstructured":"Hanover JA, Love DC, Prinz WA (2009) Calmodulin-driven nuclear entry: trigger for sex determination and terminal differentiation. J Biol Chem 284:12593\u201312597","journal-title":"J Biol Chem"},{"key":"1338_CR44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/jcb.20677","volume":"97","author":"H Yagisawa","year":"2006","unstructured":"Yagisawa H et al (2006) Nucleocytoplasmic shuttling of phospholipase C-\u03b41: a link to Ca2+. J Cell Biochem 97:233\u2013243","journal-title":"J Cell Biochem"},{"key":"1338_CR45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cdd.2009.112","volume":"17","author":"D Bano","year":"2009","unstructured":"Bano D, Dinsdale D, Cabrera-Socorro A et al (2009) Alteration of the nuclear pore complex in Ca2+-mediated cell death. Cell Death Differ 17:119\u2013133","journal-title":"Cell Death Differ"},{"key":"1338_CR46","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.3390\/cancers8030035","volume":"8","author":"M El-Tanani","year":"2016","unstructured":"El-Tanani M, Dakir E-H, Raynor B, Morgan R (2016) Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8:E35","journal-title":"Cancers"},{"key":"1338_CR47","first-page":"229","volume":"21","author":"Y Yao","year":"2009","unstructured":"Yao Y, Dong Y, Lin F et al (2009) The expression of Crm1 is associated with prognosis in human osteosarcoma. Oncol Rep 21:229\u2013235","journal-title":"Oncol Rep"},{"key":"1338_CR48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cells4030538","volume":"4","author":"A Dickmanns","year":"2013","unstructured":"Dickmanns A, Monecke T, Ficner R (2013) Structural basis of targeting the exportin CRM1 in cancer. Cells 4:538\u2013568.","journal-title":"Cells"},{"key":"1338_CR49","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1158\/0008-5472.CAN-09-0484","volume":"69","author":"J Turner","year":"2009","unstructured":"Turner J, Marchion D, Dawson J et al (2009) Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by\u00a0CRM1\u00a0inhibition. Cancer Res 69:6899\u20136905","journal-title":"Cancer Res"},{"key":"1338_CR50","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/1535-7163.MCT-15-0104","volume":"14","author":"S Kazim","year":"2015","unstructured":"Kazim S, Malafa M, Coppola D et al (2015) Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol Cancer Ther 14:1570\u20131581","journal-title":"Mol Cancer Ther"},{"key":"1338_CR51","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"Z Hing","year":"2015","unstructured":"Hing Z, Mantel R, Beckwith K et al (2015) Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood 125:3128\u20133132","journal-title":"Blood"},{"key":"1338_CR52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11912-001-0007-6","volume":"3","author":"S Kumar","year":"2001","unstructured":"Kumar S, Goldberg R (2001) Adjuvant chemotherapy for colon cancer. Curr Oncol Rep 3:94\u2013101","journal-title":"Curr Oncol Rep"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-016-1338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-016-1338-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-016-1338-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T03:38:22Z","timestamp":1601264302000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-016-1338-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,20]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s10495-016-1338-y","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,20]]}}}